Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 89Leukemia 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma 26Leukemia, Erythroblastic, Acute 19Leukemia, Myelomonocytic, Acute 18Leukemia, Monocytic, Acute 18Leukemia, Megakaryoblastic, Acute 18Congenital Abnormalities 13Burkitt Lymphoma 13Lymphoma, Large B-Cell, Diffuse 12Myelodysplastic Syndromes 10Lymphoma, Non-Hodgkin 10Anemia, Refractory, with Excess of Blasts 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma, Follicular 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Eosinophilic, Acute 6Recurrence 5Myeloproliferative Disorders 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Promyelocytic, Acute 5Leukemia, Biphenotypic, Acute 5Leukemia, Basophilic, Acute 5Hodgkin Disease 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Multiple Myeloma 4

Interventions

Doxorubicin 6Vincristine 4Liposomes 4Bleomycin 4Fluorouracil 2sargramostim 1liposomal doxorubicin 1Zidovudine 1Watchful Waiting 1Radiotherapy 1Paclitaxel 1Observation 1Methotrexate 1Light Coagulation 1Leucovorin 1Laser Therapy 1Isotretinoin 1Imiquimod 1Dexamethasone 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Cisplatin 1Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Acquired Immunodeficiency Syndrome × Cytarabine × Clear all
NCT00000658 2021-11-03

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 3 Completed
250 enrolled
Lymphoid

Acquired Immunodeficiency Syndrome, Lymphoma, Non-Hodgkin, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡